Pakistan private patient pathway: tertiary hospitals and named-patient access to innovator medicines
By Reserve Meds · Clinical and regulatory team · Last reviewed 2026-05-17
Why the private pathway matters
Pakistan's public-sector healthcare carries the population's burden of care but is structurally not set up for routine FDA-approved innovator imports outside specific federal programmes (HCV elimination, immunisation, TB, HIV). For patients with rare-disease, advanced oncology, autoimmune, or neurology prescriptions that depend on innovator-grade biologics or small-molecule agents, the practical route is through major private and trust-sector tertiary centres.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How the coordination works
Step 1: Diagnosis and treatment plan with a credentialed specialist registered with the Pakistan Medical Commission (PMC), typically at one of the centres above.
Step 2: If the FDA-approved therapy is not locally registered or not routinely available, the specialist initiates a DRAP Personal Use Import / Named Patient file via the OIES portal at dra.gov.pk. Reserve Meds can supply the documentation template and regulatory liaison.
Step 3: US-side innovator sourcing via Reserve Meds's DSCSA-compliant wholesale partners, cold-chain shipping where required, customs clearance through a Pakistani importer of record, and delivery to the hospital pharmacy.
Step 4: Hospital pharmacy receipt, chain-of-custody verification, and administration in the infusion suite or outpatient pharmacy dispensing per the drug profile. Follow-up monitoring per FDA labelling, coordinated by the prescribing specialist.
State Bank of Pakistan FX considerations
Outward remittance for medical treatment is governed by State Bank of Pakistan FX regulations. Under SBP FE Circular No. 8 of 2015, authorised dealer banks may remit foreign exchange for treatment abroad up to a set limit, paid directly to the foreign hospital; larger amounts go to SBP for approval. Authorised dealers (Pakistani commercial banks with FX dealing licence) execute the wire against documented medical-purpose evidence (physician letter, hospital invoice, Reserve Meds quote).
Annual SBP medical-purpose remittance allowances apply per individual; supplementary approvals are available for cases above the standard ceiling, typically with hospital-letter documentation.
Indicative timing
We give you a written timeline estimate for your case before you commit. Reserve Meds coordinates intake on a rolling basis; capacity is finite.
Frequently asked
Can a public-sector specialist file a DRAP OIES application? Yes, any PMC-registered specialist can. The OIES filing is keyed to the prescribing physician's credentials, not to the employing institution.
Does the hospital charge its own fees on top of Reserve Meds? Hospital pharmacy receipt-and-administration fees and infusion-suite charges are billed by the hospital separately from the drug cost and Reserve Meds coordination. The patient pays the hospital directly for hospital-rendered services.
Can the importer of record be the hospital pharmacy directly? Yes, where the hospital pharmacy holds the necessary import licence and elects to act as IOR. Reserve Meds also coordinates with licensed third-party Pakistani IORs where preferred.
What happens at refill time? DRAP Personal Use Import approvals support renewal cycles aligned to the prescription calendar. Reserve Meds maintains case continuity so each refill is not a fresh file.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US to overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-17.
Regulatory framework and the private-patient named-patient innovator access pathway in Pakistan, 2026
The Drug Regulatory Authority of Pakistan (DRAP) is the federal regulatory authority that governs medicine registration, manufacturing, and import in Pakistan. The official regulator portal is at www.dra.gov.pk; the locally registered medicines list is at www.dra.gov.pk/registered-drugs. The DRAP-administered One-Stop Industrial and Entrepreneur Services (OIES) portal handles the named-patient and personal-import application stream for reference-authority-approved medicines that are not yet held on the locally registered list at the time the case opens.
The qualifying conditions are stable across the recent regulatory cycle. The medicine must be approved by a recognised reference authority (US Food and Drug Administration or European Medicines Agency qualifies). No locally available alternative is clinically equivalent for the specific patient indication. The treating physician of record takes documented clinical responsibility. Chain of custody is preserved end to end from the source country (the US under Drug Supply Chain Security Act handling for Reserve Meds cases) through international transit to the named dispensing facility. The application is filed by the treating physician and the receiving institutional pharmacy through OIES; Reserve Meds provides the upstream sourcing, chain-of-custody documentation, and international shipping that the institutional pharmacy then attaches to its OIES file.
Tertiary centres and clinical coordination in Pakistan
Pakistan's tertiary centres carry the haematology, oncology, neurology, metabolic, infectious-disease, and rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For high-complexity therapies that need specialised infusion infrastructure, baseline organ-function workup, or post-treatment monitoring, the case is routinely referred to one of these centres from the outset.
For oral, subcutaneous, and standard in-clinic infusion therapies that can be administered in Pakistan once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Medicines are supplied through a US-licensed pharmaceutical wholesale partner under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, and Reserve Meds coordinates international shipment to the named dispensing facility and re-supply aligned to the dosing schedule. For therapies that require US-certified treatment center administration (some cell, gene, and complex biologics fall in this bucket), the practical access pathway shifts to patient travel; the Pakistan tertiary team continues to handle upstream referral package assembly and the long-term follow-up after the patient returns home.
Pakistan quotes and payer posture for private-patient named-patient innovator access, 2026
Reserve Meds issues a written, itemised custom quote once the treating physician's documentation is in. Medicine price: quote on request. You get a written quote for your case before you commit. Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, Reserve Meds coordination, and any patient and caregiver travel and accommodation are itemised separately on every quote.
Payer posture in Pakistan for the private-patient named-patient innovator access pathway is overwhelmingly cash-pay. The relevant federal scheme is Sehat Sahulat Program (provincial) and out-of-pocket spending dominates specialty cases; the portal is at sehat.gov.pk. Public coverage generally does not extend to non-locally-registered specialty named-patient cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers in the private-patient named-patient innovator access pathway and how Reserve Meds clears them
The five barriers that most often delay a private-patient named-patient innovator access case in Pakistan are: (1) Regulatory documentation completeness. The DRAP OIES named-patient application package requires a specific bundle (physician clinical rationale letter, prescription with full strength and quantity, patient identifier, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent). Reserve Meds provides physician-facing templates aligned to the format the reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with US-licensed pharmaceutical wholesale partners under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) Clinical eligibility documentation. The treating consultant at the prescribing tertiary centre defines eligibility against the FDA labelled indication and the relevant clinical-practice guideline; Reserve Meds does not adjudicate the clinical decision. (4) Family logistics. Patient and caregiver travel where applicable, accommodation near the treatment center where applicable, in-country transport, translator support where needed, and post-treatment data flow back to the treating Pakistan physician are coordinated as a single arc rather than as fragmented vendor handoffs. (5) Funding and remittance mechanics. Cash-pay is the default.
The Reserve Meds operating posture across the five barriers is the same in every Pakistan case: we resolve the operational, regulatory, sourcing, and logistics work; the treating physician of record holds the clinical authority; the family holds the funding and the final go/no-go.
Recent regulatory and access news for the private-patient named-patient innovator access pathway in Pakistan, 2026
The Drug Regulatory Authority of Pakistan (DRAP) portal at www.dra.gov.pk and the locally registered medicines list at www.dra.gov.pk/registered-drugs are the authoritative source for the current Pakistan listing status of any specific medicine; the snapshot date governs. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages are the authoritative sources for any active safety advisory or supply-side shortage signal over the most recent 12-month window. The State Bank of Pakistan medical-remittance framework guidance at sbp.org.pk epd governs outward remittance for treatment abroad. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.